Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
UroGen Pharma
UroGen Pharma
(URGN)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Jelmyto
Mitomycin
2020-04-15
2026-2031
Colorectal neoplasms
,
Pancreatic neoplasms
,
Stomach neoplasms
,
Urinary bladder neoplasms
,
Adenocarcinoma
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Mitomycin
pancreatic neoplasms
ZALIFRELIMAB
urologic neoplasms
,
carcinoma
,
urinary bladder neoplasms
,
non-muscle invasive bladder neoplasms
Mephedrone
carcinoma
,
colorectal neoplasms
,
neoplasms
,
neoplasm metastasis
,
peritoneal neoplasms
Azzalure
thoracic outlet syndrome
,
essential tremor
,
paresis
,
snoring
,
paraplegia
,
obstructive sleep apnea
,
sleep apnea syndromes
,
postherpetic neuralgia
,
peripheral nerve injuries
,
cerebral palsy
,
traumatic brain injuries
,
stroke
,
blepharospasm
,
sialorrhea
,
healthy volunteers/patients
,
atrial fibrillation
,
cardiac surgical procedures
,
intellectual disability
,
parkinson disease
,
pruritus
,
hyperpigmentation
,
migraine disorders
,
clostridium botulinum type a
,
muscle spasticity
,
torticollis
,
dystonic disorders
,
dystonia
,
sleep bruxism
,
bruxism
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use